In particular, a joint consensus statement from the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) suggested that PCSK9 use should be considered in patients with clinical ASCVD treated with maximal tolerated statin therapy and/or ezetimibe but still showing LDL-C >140 mg/dL (>3.6 mmol/L) or LDL-C >100 mg/dL (>2.6 mmol/L) in the absence/presence of indices of risk severity, such as familial hypercholesterolemia, diabetes mellitus or severe/extensive ASCVD [15]. Here, PCSK9 is linked to familial hypercholesterolemia.